Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-
Clinical Trials
Related News

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2009-07-28
Last Posted Date
2013-08-22
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
9
Registration Number
NCT00947388
Locations
🇺🇸

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment

Phase 2
Withdrawn
Conditions
Leukemia
First Posted Date
2009-07-15
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00939328

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: bendamustine
Drug: bortezomib
First Posted Date
2009-06-15
Last Posted Date
2012-10-04
Lead Sponsor
Cephalon
Target Recruit Count
40
Registration Number
NCT00920855
Locations
🇺🇸

Family Cancer Center, PLLC, Collierville, Tennessee, United States

🇺🇸

Pacific Oncololgy & Hematology, Encinitas, California, United States

🇺🇸

James R. Berenson, M.D., Inc., West Hollywood, California, United States

and more 10 locations

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Melphalan
Drug: Bendamustine
First Posted Date
2009-06-09
Last Posted Date
2019-06-04
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
57
Registration Number
NCT00916058
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

First Posted Date
2009-05-14
Last Posted Date
2020-04-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
14
Registration Number
NCT00901927
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2009-05-12
Last Posted Date
2020-01-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
39
Registration Number
NCT00899431
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

Phase 2
Completed
Conditions
Mantle Cell Lymphoma
Interventions
Drug: Bendamustine
Drug: Rituximab
First Posted Date
2009-05-01
Last Posted Date
2014-11-04
Lead Sponsor
Cephalon
Target Recruit Count
45
Registration Number
NCT00891839
Locations
🇺🇸

Teva Investigational Site 11, Fountain Valley, California, United States

🇺🇸

Teva Investigational Site 41, Grapevine, Texas, United States

🇺🇸

Teva Investigational Site 35, Orlando, Florida, United States

and more 10 locations

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

First Posted Date
2009-04-14
Last Posted Date
2019-06-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT00880815
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Phase 1
Terminated
Conditions
Brain Metastases
Interventions
Drug: Bendamustine
First Posted Date
2009-04-09
Last Posted Date
2012-12-18
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
12
Registration Number
NCT00879073
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

First Posted Date
2009-04-07
Last Posted Date
2018-02-05
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
447
Registration Number
NCT00877006
Locations
🇺🇸

Teva Investigational Site 52, Fountain Valley, California, United States

🇺🇸

Teva Investigational Site 72, Augusta, Georgia, United States

🇺🇸

Teva Investigational Site 48, Chicago, Illinois, United States

and more 125 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy